All In Biotech

Drug Trial Radar · NCT05397639

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

375

Planned (sponsor's estimate)

Start

Nov 1, 2022

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Suven Life Sciences LimitedIndustry
Sponsor type
Industry
First posted
May 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

Conditions

  • Agitation
  • Alzheimer's Type Dementia

Interventions

  • Masupirdine 50 mgDrug

    Tablet, Once Daily

  • Masupirdine 100 mgDrug

    Tablet, Once Daily

  • PlaceboDrug

    Matching Placebo Tablet, Once Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohen-Mansfield Agitation Inventory (CMAI)Time frame: From Baseline to Week 12 visit

Locations

44 sites in 4 countries. Site status is shown where the registry gives one.

  • Advanced Research Center, Inc.

    Anaheim, California

  • ATP Clinical Research, Inc.

    Costa Mesa, California

  • Leading Edge Research LA, LLC

    Encino, California

  • Neuro Pain Medical Center

    Fresno, California

  • Neurology Center of North Orange County

    Fullerton, California

  • Mary S Easton Center for Alzheimer's Research and Care UCLA

    Los Angeles, California

  • Ki Health Partners, LLC

    Stamford, Connecticut

  • Allied Biomedical Research Institute

    Miami, Florida

  • Central Miami Medical Institute

    Miami, Florida

  • CCM Clinical Research Group

    Miami, Florida

  • Miami Jewish Health

    Miami, Florida

  • Novel Clinical Research Center, LLC.

    Miami, Florida

  • Brainstorm Research

    Miami, Florida

  • Combined Research Orlando Phase I-IV

    Orlando, Florida

  • Quantum Laboratories Inc

    Pompano Beach, Florida

  • Re:Cognition Health

    Chicago, Illinois

  • Insight Hospital and Medical Center Chicago

    Chicago, Illinois

  • Ocean Medical Research

    Toms River, New Jersey

  • Dent Neurologic Institute

    Amherst, New York

  • Velocity Clinical Research, Syracuse

    East Syracuse, New York

  • Velocity Clinical Research, Cleveland

    Beachwood, Ohio

  • Ralph H. Johnson VA Health Care System

    Charleston, South Carolina

  • Midlands Neurology and Pain Associates

    Columbia, South Carolina

  • Gadolin Research

    Beaumont, Texas

  • Re:Cognition Health

    Fort Worth, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Clinical Trial Network

    Houston, Texas

  • Clinical Hospital Center Rijeka

    Rijeka, Croatia

  • Polyclinic Neuron

    Zagreb, Croatia

  • University Hospital Center Zagreb

    Zagreb, Croatia

  • Klinika za psihijatriju Vrapce

    Zagreb, Croatia

  • ClinHouse Centrum Medyczne

    Zabrze, Poland

  • Medycyna Milorzab sp. z o.o.

    Lodz, Lódzkie, Poland

  • FutureMeds Warszawa Centrum

    Warsaw, Masovian Voivodeship, Poland

  • MTZ Clinical Research powered by Pratia

    Warsaw, Masovian Voivodeship, Poland

  • Centrum Leczenia Zaburzen Pamieci Affidea

    Warsaw, Masovian Voivodeship, Poland

  • Centrum Medyczne Silmedic Sp z o o

    Katowice, Silesian Voivodeship, Poland

  • EMC Silesia Sp. z o.o.

    Katowice, Silesian Voivodeship, Poland

  • Neuro-Medic Janusz Zbrojkiewicz

    Katowice, Silesian Voivodeship, Poland

  • Clinical Hospital Center Dragisa Misovic Dedinje

    Belgrade, Serbia

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.